Medplus Health Services Limited , a prominent player in the Indian pharmacy retail sector, has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores in Telangana. The company made this announcement in a regulatory filing to the stock exchanges on September 9, 2025.

Suspension Details

The Assistant Director of Drugs Control Administration, Secunderabad, issued the suspension orders on September 8, 2025, affecting two stores:

1. West Marredpally Circle store: Suspended for one day
2. Vijayapuri Colony South Lalaguda Road store: Suspended for four days

These suspensions were imposed under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

Medplus has estimated the potential revenue losses from these suspensions:

Regulatory Compliance

The company has made this disclosure in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, MedPlus has adhered to the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Transparency Measures

MedPlus has stated that the details of this matter will be available on the company's website ( www.medplusindia.com ) as well as on the websites of BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Ltd. ( www.nseindia.com ).

While the immediate financial impact appears limited, this incident highlights the regulatory challenges faced by pharmacy retail chains in India and the importance of maintaining compliance with drug licensing regulations.

Medplus Health Services has reported that its subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension order for a drug license at one of its stores in Telangana. The suspension was issued by the Assistant Director of Drugs Control Administration, Shameerpet, Telangana.

Suspension Details

The suspension order affects a store located in Boduppal Brundavan Colony, Telangana. According to the company's disclosure, the suspension was due to violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

Medplus Health Services estimates that the two-day suspension could result in a potential revenue loss of approximately Rs. 0.81 lacs for the affected store.

Regulatory Compliance

The company has promptly disclosed this information in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure aligns with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Company Response

Manoj Kumar Srivastava, Company Secretary & Compliance Officer of Medplus Health Services, has confirmed that the details of this matter will be available on the company's website ( www.medplusindia.com ) as well as on the websites of BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Ltd. ( www.nseindia.com ).

While the immediate financial impact appears limited, this incident highlights the importance of regulatory compliance in the pharmaceutical retail sector. Investors and stakeholders may want to monitor how Medplus addresses this issue and implements measures to prevent similar occurrences in the future.